Effects of Glossopharyngeal Insufflation in Ankylosing Spondylitis: A Pilot Study

Table 2

Individual results from baseline (pre) and follow-up after 12 weeks (post) of Glossopharyngeal Insufflation for the six patients fulfilling the study protocol.

	Case  1		Case  2		Case  3		Case  4		Case  5		Case  6
	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
VC^1, L	4.84	5.18	5.63	4.94	3.68	3.95	3.11	3.14	5.79	5.69	5.56	5.89
PEF^2, L/min	557	605	545	539	561	528	589	559	586	491	625	656
C7-30, cm	5.0	5.5	6.0	5.5	3.5	3.5	0.5	1.0	3.0	—	2.0	4.0
Tragus-wall, cm	10	9.5	11.5	11.5	11.5	11.0	18	17.0	10.5	—	16	13..5
BX^3 diff, cm	7.0	8.5	6.0	7.5	2.0	4.0	4.0	5.0	6.0	—	7.0	9.5
BC^4 diff, cm	9.5	11.5	4.5	6.5	3.0	3.5	2.0	2.0	4.0	—	6.0	8.0
BAS DAI^5, 0–10	3.4	3.4	0.4	1.3	1.8	2.0	1.5	2.3	2.3	—	0.7	0.8
BASFI^6, 0–10	0.6	0.25	0.2	0.7	1.5	2.0	1.0	1.0	1.1	—	2.1	1.9
BASG1^7, 0–10	1.6	2.4	0.4	2.6	2.5	2.3	0.2	0.3	1.9	—	0.6	1.2
VCGI^8 (L)		6.75		5.40		4.05		3.57		5.76		7.78
VC increase with GI (%)		30.3		1.4		2.5		13.7		1.2		32.1

Vital capacity (VC), peak expiratory flow (PEF), level of xiphoid process on the chest wall (BX) difference of inhalation and exhalation, ⁴level of the fourth costae on the chest wall (BC) difference of inhalation and exhalation, ⁵the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), ⁶the Bath Ankylosing Spondylitis Functional Index (BASFI), ⁷the Bath Ankylosing Spondylitis Global Index (BASG1), and ⁸vital Capacity using Glossopharyngeal Insufflation (VCGI).